Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Oppenheimer upped their Q1 2019 earnings estimates for shares of Neurocrine Biosciences in a research note issued on Tuesday, March 12th. Oppenheimer analyst J. Olson now expects that the company will post earnings of ($1.03) per share for the quarter, up from their previous estimate of ($1.08). Oppenheimer has a “Outperform” rating and a $110.00 price objective on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ Q4 2019 earnings at $0.55 EPS, FY2019 earnings at $1.04 EPS and FY2020 earnings at $3.92 EPS.
Several other equities research analysts have also recently weighed in on the company. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, February 8th. Cantor Fitzgerald restated a “buy” rating and set a $121.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, December 12th. JPMorgan Chase & Co. cut Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $97.00 to $100.00 in a research note on Wednesday, January 23rd. Stifel Nicolaus cut their target price on Neurocrine Biosciences from $115.00 to $17.07 and set a “buy” rating for the company in a research note on Wednesday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $102.00 target price on shares of Neurocrine Biosciences in a research note on Tuesday, January 15th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Neurocrine Biosciences presently has a consensus rating of “Buy” and a consensus price target of $102.56.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. The firm had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. During the same period in the prior year, the company earned $0.07 earnings per share. The company’s quarterly revenue was up 39.1% on a year-over-year basis.
In related news, insider Eiry Roberts sold 1,857 shares of the stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $84.09, for a total value of $156,155.13. Following the completion of the sale, the insider now directly owns 3,143 shares in the company, valued at $264,294.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin Charles Gorman sold 7,614 shares of the stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total value of $671,250.24. Following the completion of the sale, the chief executive officer now owns 408,082 shares of the company’s stock, valued at $35,976,509.12. The disclosure for this sale can be found here. Insiders sold a total of 13,280 shares of company stock valued at $1,163,054 over the last quarter. 4.30% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC increased its holdings in Neurocrine Biosciences by 8.7% in the fourth quarter. SG Americas Securities LLC now owns 1,971 shares of the company’s stock valued at $141,000 after purchasing an additional 157 shares during the period. Sumitomo Life Insurance Co. increased its holdings in Neurocrine Biosciences by 1.8% in the fourth quarter. Sumitomo Life Insurance Co. now owns 9,939 shares of the company’s stock valued at $710,000 after purchasing an additional 180 shares during the period. Rehmann Capital Advisory Group increased its holdings in Neurocrine Biosciences by 54.7% in the third quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock valued at $68,000 after purchasing an additional 197 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Neurocrine Biosciences by 7.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,116 shares of the company’s stock valued at $437,000 after purchasing an additional 448 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at $32,000.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Recommended Story: Return on Equity (ROE)
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.